Special Issue

Radiotherapy Combined Immunotherapy

Message from the Guest Editors

Radiotherapy (RT), a central module of cancer treatment, has the most appropriate nonsurgical modalities. This type of treatment is received by about half of all patients with cancer. RT is an influential treatment for both curative purposes, as well as for palliation and the maintenance of patients' quality of life. Recently, investigations have had several prime focuses regarding new technologies, such as FLASH RT, proton RT, and carbon ion RT, which aim to improve therapeutic efficacy in patients. The increasing evidence on the immunomodulatory effects of RT casts new light on the systemic antitumor response. This Special issue aims to deliver high-quality research with the goal of highlighting new treatment strategies, including X-rays, Proton therapy, and C-ion therapy, importantly, to target cancer stem cells and treat various cancers. We encourage contributors to submit manuscripts addressing any of the different aspects of radiation therapy and/or immunotherapy, including: radiation-combined immunotherapy; NK cells; new pharmacological drugs; radiation therapy, including X-rays, C-ions, Proton, and FLASH therapy; and basic and translational research.

Guest Editors

Dr. D. S. Prabakaran

Department of Radiation Oncology, College of Medicine, Chungbuk National University, Chungdae-ro 1, Seowon-gu, Cheongju 28644, Republic of Korea

Dr. Walter Tinganelli

Biophysics Division, GSI Helmholtz Center for Heavy Ion Research, 64291 Darmstadt, Germany

Deadline for manuscript submissions

closed (30 June 2024)

Radiation

an Open Access Journal by MDPI

Indexed in Scopus

mdpi.com/si/152557

Radiation
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
radiation@mdpi.com

mdpi.com/journal/radiation

Radiation

an Open Access Journal by MDPI

Indexed in Scopus

mdpi.com/journal/radiation

MDPI

About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Gabriele Multhoff
Central Institute for Translational Cancer Research (TranslaTUM), Klinikum rechts der Isar der Technischen Universität München, 81675 Munich, Germany

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25.5 days after submission; acceptance to publication is undertaken in 5.1 days (median values for papers published in this journal in the first half of 2025).